GKOS Glaukos Corp

$91.58

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About Glaukos Corp

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.

Website: https://www.glaukos.com

Sector
LIFE SCIENCES
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1192448
Address
229 AVENIDA FABRICANTE, SAN CLEMENTE, CA, US
Valuation
Market Cap
$5.15B
P/E Ratio
nan
PEG Ratio
1.64
Price to Book
6.72
Performance
EPS
$-2.77
Dividend Yield
—
Profit Margin
-38.20%
ROE
-23.80%
Technicals
50D MA
$111.81
200D MA
$129.21
52W High
$163.71
52W Low
$77.91
Fundamentals
Shares Outstanding
57M
Target Price
$157.46
Beta
0.88

GKOS EPS Estimates vs Actual

● Estimated
● Actual

GKOS News & Sentiment

Nov 11, 2025 • Benzinga NEUTRAL
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans - Sight Sciences ( NASDAQ:SGHT )
MENLO PARK, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc. ( NASDAQ:SGHT ) ( Sight Sciences, or the Company ) , an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced ...
Nov 06, 2025 • Motley Fool NEUTRAL
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings
On Tuesday, Baltimore-based Brown Capital Management reported selling 861,020 shares of Vericel Corporation for an estimated $30.9 million based on the average share price in the third quarter.According to a filing with the Securities and Exchange Commission released Tuesday, Brown Capital ...
Nov 06, 2025 • Motley Fool NEUTRAL
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.Brown Capital Management disclosed in an SEC filing on Tuesday that it reduced its holding in Glaukos Corporation ( ...
Oct 30, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
The company's recent past featured robust growth, and it anticipates continued rises into the near future.
Oct 30, 2025 • Motley Fool SOMEWHAT-BULLISH
Glaukos ( GKOS ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Oct. 29, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
Sentiment Snapshot

Average Sentiment Score:

0.248
50 articles with scored sentiment

Overall Sentiment:

Bullish

GKOS Reported Earnings

Jul 30, 2025
Jun 30, 2025 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.24
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: 7.7%
Apr 30, 2025
Mar 31, 2025 (Pre market)
0.14 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: 38.1%
Feb 20, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: -3.0%
Nov 04, 2024
Sep 30, 2024 (Post market)
0.2 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: 41.7%
Jul 31, 2024
Jun 30, 2024 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.52
  • Estimate: $-0.51
  • Whisper: —
  • Surprise %: -2.0%
May 01, 2024
Mar 31, 2024 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.57
  • Whisper: —
  • Surprise %: -22.8%
Feb 21, 2024
Dec 31, 2023 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.63
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: -14.6%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.05 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: 9.1%
Aug 02, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.55
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: 0.0%

Financials